Loading...
XSHE000590
Market cap239mUSD
Dec 25, Last price  
7.17CNY
1D
-2.27%
1Q
27.80%
Jan 2017
-62.80%
Name

Tus Pharmaceutical Group Co Ltd

Chart & Performance

D1W1MN
XSHE:000590 chart
P/E
68.01
P/S
4.24
EPS
0.11
Div Yield, %
0.24%
Shrs. gr., 5y
—
Rev. gr., 5y
16.84%
Revenues
405m
+15.44%
267,089,665271,110,822286,824,832207,905,036236,573,558274,089,961311,624,913343,508,517363,420,444256,000,679203,122,000294,719,555317,410,504343,539,198185,811,015315,034,457275,090,121300,774,612350,528,110404,647,908
Net income
25m
+39.41%
5,426,3304,290,0122,894,26120,517,35020,374,461047,153,71372,134,381137,606,3350022,372,28255,175,21519,173,756042,442,30822,722,39735,438,60318,109,85425,246,778
CFO
-28m
L
48,459,52755,959,294068,039,94934,885,63234,144,67784,978,22630,866,20619,746,0604,122,1590000654,23729,208,43651,480,57925,196,29654,473,687-28,394,717
Dividend
Jun 21, 20130.2 CNY/sh

Profile

Tus-Pharmaceutical Group Co., Ltd. manufactures and sells traditional Chinese medicine and western medicine products. The company was formerly known as Tus-Guhan Group Corp.,Ltd. Tus-Pharmaceutical Group Co., Ltd. was founded in 1956 and is based in Hengyang, China.
URL
http://www.guhan.com/
IPO date
Jan 19, 1996
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
404,648
15.44%
350,528
16.54%
300,775
9.34%
Cost of revenue
271,290
261,211
198,108
Unusual Expense (Income)
NOPBT
133,358
89,317
102,666
NOPBT Margin
32.96%
25.48%
34.13%
Operating Taxes
4,789
3,704
6,398
Tax Rate
3.59%
4.15%
6.23%
NOPAT
128,569
85,614
96,268
Net income
25,247
39.41%
18,110
-48.90%
35,439
55.96%
Dividends
(4,195)
(338)
(63)
Dividend yield
0.20%
0.02%
0.00%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
10,000
38,616
3,000
Long-term debt
86,141
100,352
11,170
Deferred revenue
44,366
46,289
Other long-term liabilities
42,720
46,095
46,625
Net debt
(114,529)
(121,562)
(311,658)
Cash flow
Cash from operating activities
(28,395)
54,474
25,196
CAPEX
(22,042)
Cash from investing activities
4,153
Cash from financing activities
(31,513)
111,520
FCF
46,970
45,052
45,685
Balance
Cash
189,770
260,530
325,827
Long term investments
20,900
Excess cash
190,437
243,004
310,789
Stockholders' equity
396,734
386,092
384,066
Invested Capital
715,999
666,934
465,030
ROIC
18.59%
15.13%
22.44%
ROCE
14.62%
9.74%
13.23%
EV
Common stock shares outstanding
239,471
239,471
239,471
Price
8.96
0.22%
8.94
-9.51%
9.88
16.51%
Market cap
2,145,663
0.22%
2,140,873
-9.51%
2,365,976
16.51%
EV
2,035,619
2,023,337
2,056,318
EBITDA
161,399
113,677
122,149
EV/EBITDA
12.61
17.80
16.83
Interest
4,462
1,154
472
Interest/NOPBT
3.35%
1.29%
0.46%